Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety, and reduce total procedural costs. The company primarily designs, develops, manufactures, and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Teleflex markets and sells its products worldwide through a combination of its direct sales force and distributors. The company's major manufacturing operations are located in the Czech Republic, Malaysia, Mexico, and the United States.

Teleflex is focused on achieving consistent, sustainable, and profitable growth and improving financial performance by increasing market share and improving operating efficiencies.

• Employees: Approximately 14,500 (as of December 31, 2023)
• Geographic Footprint: 34 countries
• Headquarters: Wayne, Pennsylvania
• Founded: 1943
• Number of locations/facilities: Approximately 90
• Revenue: $2.97 billion (FY2023)
• Key Subsidiaries/Brands: Arrow, LMA, Rusch, QuikClot, Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, Titan SGS, UroLift

• CEO: Liam J. Kelly
• CFO: Thomas E. Powell
• Corporate Vice President, Human Resources and Communications: Cameron P. Hicks
• Corporate Vice President, General Counsel and Secretary: Daniel V. Logue
• Corporate Vice President and President, Global Commercial: Jay White
• Corporate Vice President, Manufacturing and Supply Chain: James Winters

Mr. Kelly has been the President and Chief Executive Officer since January 2018 and Chairman of the Board since May 2020. Mr. Powell has been the Executive Vice President and Chief Financial Officer since February 2013.

• Annual Revenue: $2.97 billion (FY2023)
• Net Income: $356.3 million
• Total Assets: $7.53 billion
• Employees: Approximately 14,500 (as of December 31, 2023)
• Key Financial Highlights: Net revenues increased by 6.6% compared to the prior year, primarily due to an increase in sales of new products, price increases, and net revenues generated by the acquired Palette and Standard Bariatrics businesses.

Teleflex's product categories include:

• Vascular Access: Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems.
• Interventional: Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, the MANTA Vascular Closure device, and Arrow OnControl powered bone biopsy system.
• Anesthesia: Laryngoscopes, supraglottic airways, endotracheal tubes, and atomization devices branded under LMA, Rusch, and MAD. Epidurals, catheters, and disposable pain pumps for regional anesthesia branded under Arrow. External hemostats, interventional products, and trauma products branded under QuikClot.
• Surgical: Metal and polymer ligating clips, fascial closure surgical systems, percutaneous surgical systems, a powered bariatric stapler, and other surgical instruments branded under Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS.
• Interventional Urology: The UroLift System and hyaluronic acid gel-based products primarily utilized in the treatment of urological diseases, including Barrigel.
• Respiratory: Humidification and oxygen therapy products.

Teleflex operates through four segments:

• Americas: Provides a comprehensive portfolio of medical technology products used by hospitals and healthcare providers.
• EMEA: Provides a comprehensive portfolio of medical technology products used by hospitals and healthcare providers.
• Asia: Provides a comprehensive portfolio of medical technology products used by hospitals and healthcare providers.
• OEM: Designs, manufactures, and supplies devices and instruments for other medical device manufacturers.

The following shows the percentage of net revenues by reportable operating segment as a percentage of total consolidated net revenues for the year ended December 31, 2023: Americas (58%), OEM (11%), EMEA (20%), Asia (11%).

Teleflex's strategy is focused on achieving consistent, sustainable, and profitable growth and improving financial performance by increasing market share and improving operating efficiencies. Key strategic initiatives include:

• Development of new products and product line extensions.
• Investment in new technologies and broadening the application of existing technologies.
• Expansion of the use of products in existing markets and introduction of products into new geographic markets.
• Achievement of economies of scale by utilizing the direct sales force and distribution network to sell new products.
• Expansion of the product portfolio through select acquisitions, licensing arrangements, and business partnerships.

Teleflex continues to execute its footprint realignment and other restructuring programs designed to improve efficiencies in manufacturing and distribution facilities and its sales and marketing and research and development organizations. The company also expects to continue to increase the size of its business through a combination of acquisitions and organic growth initiatives.

Teleflex operates in the highly competitive medical device industry, competing with a range of companies from small start-ups to large, established corporations. The company competes primarily on the basis of clinical superiority and innovative features that enhance patient benefit, product reliability, performance, customer and sales support, and cost-effectiveness. The medical device industry is characterized by extensive product research and development and rapid technological advances.

• Market Risks: Strong competition in the medical device industry; failure to successfully develop and market new products; dependence on third-party coverage and reimbursements; and the impact of healthcare reform.
• Operational Risks: Extensive government regulation; disruptions in sterilization of products; disruptions in manufacturing or distribution; reliance on key suppliers; and failure to maintain strong relationships with physicians and other healthcare professionals.
• Financial Risks: Volatility in domestic and global financial markets; substantial indebtedness; and fluctuations in foreign currency exchange rates, commodity prices and interest rates.
• Regulatory Risks: Healthcare fraud and abuse laws; the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws; and failure to comply with those laws.